Organogenesis says PuraPly AM diabetic foot ulcer trial meets 12-week closure endpoint

Organogenesis -4.18% Pre

Organogenesis

ORGO

2.29

2.25

-4.18%

-1.75% Pre
  • Organogenesis completed a randomized controlled trial of PuraPly AM in non-healing diabetic foot ulcers.
  • Study met primary endpoint, showing better wound closure with PuraPly AM plus standard of care versus standard of care alone.
  • Organogenesis plans to publish results in a peer-reviewed journal, positioning data to support future coverage decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.